Startup Profiles: Upstream Gets $200m for Asthma Antibody; Transition Fetches $50m for Condensate Drug Discovery

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Startup Profiles: Upstream Bio Gets Another $200M, Kate Therapeutics Debuts with $51M
Going Upstream Against Inflammation: Samantha Truex on The Long Run